Abbott To Bolster Biaxin XL Patent Protection Ahead Of Compound Expiration In May
This article was originally published in The Pink Sheet Daily
Executive Summary
The additional intellectual property for the extended-release formulation will give generic firms “something to think about,” Abbott CFO Freyman says at SG Cowen investor conference. Abbott says it filed suit against three generic manufacturers March 14.
You may also be interested in...
Abbott To Assert New Biaxin XL Patent In Ongoing Suits
Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12
Abbott To Assert New Biaxin XL Patent In Ongoing Suits
Abbott is asserting its new pharmacokinetic patent issued for Biaxin XL (clarithromycin extended-release) in ongoing litigation, the company said during its earnings call April 12
Biaxin Transition: XL Accounts For 65% Of Franchise Sales
Biaxin XL (extended-release clarithromycin) accounts for approximately 65% of sales of the Biaxin franchise, Abbott said Jan. 18